| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-48 | |
| Phytochemical name or plant extracts | Rhamnazin | |
| PMID | 25704088 | |
| Literature evidence | Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. | |
| IUPAC name | 3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxychromen-4-one | |
| Phytochemicals’ class or type of plant extracts | Flavonoid | |
| Source of phytochemicals or plant Extracts | Retama sphaerocarpa | |
| Geographical availability | Algeria, Mauritania, Morocco, Portugal, Spain, Tunisia | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Renal cancer, Skin cancer | |
| Target gene or protein | VEGFR2 | |
| Gene or Protein evidence | In addition, it inhibited vascular endothelial growth factor (VEGF)-induced phosphorylation of VEGFR2 and its downstream signaling regulator in HUVECs. | |
| Target pathways | NA | |
| IC50 | 9.7 μM against MCF-7 | |
| Potency | Oral administration of rhamnazin at a dose of 200 mg/kg/day could markedly inhibited human tumor xenograft growth and decreased microvessel densities (MVD) in tumor sections. They produce a dose-dependent inhibition of cell growth at concentrations in the 10(-6)-10(-4) M and 25-250 microg/ml range for the flavonoids and extracts respectively, being the flavonol rhamnazin the most cytotoxic. | |
| Cell line/ mice model | MDA-MB-231/xenograft, TK-10, MCF-7, UACC-62 | |
| Additional information | Taken together, these preclinical evaluations suggest that rhamnazin inhibits angiogenesis and may be a promising anticancer drug candidate. They produce a dose-dependent inhibition of cell growth at concentrations in the 10(-6)-10(-4) M and 25-250 microg/ml range for the flavonoids and extracts respectively, being the flavonol rhamnazin the most cytotoxic. | |
| PubChem ID | 5320945 | |
| Additional PMIDs | 10739098 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:517091-1 | |
| Safety | NA |